Walleye Trading’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-4,407
| Closed | -$240K | – | 4345 |
|
|
2025
Q3 | $239K | Buy |
4,407
+3,307
| +301% | +$189K | ﹤0.01% | 3239 |
|
|
2025
Q2 | $60.5K | Sell |
1,100
-2,183
| -66% | -$129K | ﹤0.01% | 3774 |
|
|
2025
Q1 | $232K | Sell |
3,283
-5,429
| -62% | -$365K | ﹤0.01% | 3002 |
|
|
2024
Q4 | $573K | Sell |
8,712
-18,167
| -68% | -$1.22M | ﹤0.01% | 2529 |
|
|
2024
Q3 | $1.89M | Sell |
26,879
-66,551
| -71% | -$5.56M | ﹤0.01% | 1711 |
|
|
2024
Q2 | $7.69M | Buy |
93,430
+84,712
| +972% | +$7.05M | 0.02% | 817 |
|
|
2024
Q1 | $761K | Sell |
8,718
-12,865
| -60% | -$1.15M | ﹤0.01% | 2468 |
|
|
2023
Q4 | $2.08M | Buy |
21,583
+7,555
| +54% | +$668K | ﹤0.01% | 1896 |
|
|
2023
Q3 | $1.24M | Sell |
14,028
-13,894
| -50% | -$1.24M | ﹤0.01% | 2183 |
|
|
2023
Q2 | $2.42M | Buy |
+27,922
| New | +$2.63M | 0.01% | 1509 |
|
|
2022
Q4 | – | Sell |
-12,174
| Closed | -$1.14M | – | 4977 |
|
|
2022
Q3 | $1.03M | Buy |
+12,174
| New | +$1.08M | ﹤0.01% | 2231 |
|
|
2022
Q2 | – | Sell |
-5,142
| Closed | -$409K | – | 5141 |
|
|
2022
Q1 | $396K | Buy |
5,142
+2,273
| +79% | +$190K | ﹤0.01% | 3138 |
|
|
2021
Q4 | $253K | Sell |
2,869
-3,602
| -56% | -$297K | ﹤0.01% | 3655 |
|
|
2021
Q3 | $500K | Buy |
6,471
+1,251
| +24% | +$98.7K | ﹤0.01% | 2911 |
|
|
2021
Q2 | $436K | Buy |
5,220
+525
| +11% | +$41.6K | ﹤0.01% | 3070 |
|
|
2021
Q1 | $355K | Sell |
4,695
-1,289
| -22% | -$105K | ﹤0.01% | 3050 |
|
|
2020
Q4 | $525K | Sell |
5,984
-3,248
| -35% | -$258K | ﹤0.01% | 2610 |
|
|
2020
Q3 | $702K | Buy |
9,232
+7,801
| +545% | +$789K | ﹤0.01% | 1937 |
|
|
2020
Q2 | $176K | Sell |
1,431
-1,152
| -45% | -$114K | ﹤0.01% | 3158 |
|
|
2020
Q1 | $218K | Sell |
2,583
-9,012
| -78% | -$777K | ﹤0.01% | 2537 |
|
|
2019
Q4 | $980K | Sell |
11,595
-802
| -6% | -$60.6K | 0.01% | 1822 |
|
|
2019
Q3 | $836K | Buy |
12,397
+2,767
| +29% | +$213K | 0.01% | 1740 |
|
|
2019
Q2 | $825K | Buy |
9,630
+8,832
| +1,107% | +$756K | 0.01% | 1754 |
|
|
2019
Q1 | $71K | Sell |
798
-3,416
| -81% | -$317K | ﹤0.01% | 3611 |
|
|
2018
Q4 | $359K | Buy |
4,214
+1,301
| +45% | +$124K | ﹤0.01% | 2821 |
|
|
2018
Q3 | $282K | Sell |
2,913
-196
| -6% | -$19.6K | ﹤0.01% | 3446 |
|
|
2018
Q2 | $293K | Buy |
+3,109
| New | +$272K | ﹤0.01% | 3311 |
|
|
2018
Q1 | – | Sell |
-5,445
| Closed | -$467K | – | 4464 |
|
|
2017
Q4 | $486K | Buy |
5,445
+4,835
| +793% | +$420K | ﹤0.01% | 2618 |
|
|
2017
Q3 | $57K | Sell |
610
-366
| -38% | -$32.3K | ﹤0.01% | 3781 |
|
|
2017
Q2 | $89K | Buy |
976
+566
| +138% | +$51.5K | ﹤0.01% | 3607 |
|
|
2017
Q1 | $36K | Sell |
410
-2,147
| -84% | -$191K | ﹤0.01% | 3924 |
|
|
2016
Q4 | $212K | Sell |
2,557
-613
| -19% | -$52.7K | ﹤0.01% | 2754 |
|
|
2016
Q3 | $293K | Buy |
3,170
+2,066
| +187% | +$195K | ﹤0.01% | 2542 |
|
|
2016
Q2 | $86K | Buy |
+1,104
| New | +$93.9K | ﹤0.01% | 3620 |
|
|
2016
Q1 | – | Sell |
-662
| Closed | -$53.9K | – | 5325 |
|
|
2015
Q4 | $69K | Buy |
662
+45
| +7% | +$4.7K | ﹤0.01% | 3601 |
|
|
2015
Q3 | $65K | Sell |
617
-1,016
| -62% | -$136K | ﹤0.01% | 3307 |
|
|
2015
Q2 | $223K | Buy |
+1,633
| New | +$202K | ﹤0.01% | 2382 |
|
Other funds holding BMRN
VPC
Walleye Trading's BMRN Position: Q4 2025 in Review
Walleye Trading sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 4,407 shares — an estimated $240K sold.
Walleye Trading first reported a position in BMRN in Q2 2015 and held it in 37 quarters. The position peaked at $7.69M in Q2 2024. 539 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.
- Walleye Trading reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
- Walleye Trading sold 4,407 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $240K.
- Walleye Trading first reported a position in BioMarin Pharmaceuticals in Q2 2015 and held it in 37 quarters.
- Walleye Trading's BioMarin Pharmaceuticals position peaked at $7.69M in Q2 2024.
- 539 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.
Based on Walleye Trading's 13F filing for Q4 2025, filed 13 Feb 2026.